{"entity":{"id":"nct06669975","kind":"trial","name":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AP402 (Part 1 Dose esclation) in advanced solid tumours, run by AP Biosciences Inc., now recruiting.","summary":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06669975 by AP Biosciences Inc., with 85 participants planned, started 2025-04-22 and due to reach its primary completion in 2026-12-01. Interventions recorded: AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06669975","url":"https://clinicaltrials.gov/study/NCT06669975"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ap-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06669975","phase":"1/2","setting":"A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","sponsor":"AP Biosciences Inc.","enrolled":85,"outcomes":[]},"route":"/trials/nct06669975/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","route":"/companies/ap-biosciences/"}]}}